{"organizations": [], "uuid": "7540c1a564c163015d6987a245d4a70e0514d871", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/28/globe-newswire-poseida-therapeutics-appoints-mark-gergen-as-chief-business-officer-and-chief-financial-officer.html", "country": "US", "domain_rank": 767, "title": "Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.022, "site_type": "news", "published": "2018-02-28T16:00:00.000+02:00", "replies_count": 0, "uuid": "7540c1a564c163015d6987a245d4a70e0514d871"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/28/globe-newswire-poseida-therapeutics-appoints-mark-gergen-as-chief-business-officer-and-chief-financial-officer.html", "ord_in_thread": 0, "title": "Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer", "locations": [], "entities": {"persons": [{"name": "mark gergen", "sentiment": "negative"}, {"name": "gergen", "sentiment": "none"}, {"name": "mark j. gergen", "sentiment": "none"}, {"name": "eric ostertag", "sentiment": "none"}, {"name": "mark", "sentiment": "none"}, {"name": "j.d.", "sentiment": "none"}], "locations": [{"name": "san diego", "sentiment": "none"}, {"name": "poseida", "sentiment": "none"}], "organizations": [{"name": "poseida therapeutics inc.", "sentiment": "negative"}, {"name": "poseida therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that Mark J. Gergen, J.D., has joined the company as chief business officer and chief financial officer.\nMr. Gergen brings significant expertise in business development, strategy, operations and finance to Poseida Therapeutics, including 25 years of experience in life sciences across a number of sectors including biopharmaceuticals, diagnostics, medical devices and cell-based therapies.\n“Mark is a successful and well-respected leader in the biotechnology industry, and a key addition to an exceptional team at Poseida,” said Eric Ostertag, M.D., Ph.D., chief executive officer at Poseida. “Mark’s combination of skill and experience growing and building biotechnology companies will be invaluable to Poseida as we pursue our next stage of company growth in the year ahead.”\nMr. Gergen has spent 20 years as a member of the executive leadership team of multiple public and private companies. Most recently he was the senior vice president and chief operating officer of Halozyme Therapeutics. Prior to Halozyme he was executive vice president of Mirati Therapeutics where he had responsibility for all business operations of the company, including functions of both COO and CFO. From 2005 until the sale of Amylin Pharmaceuticals to Bristol-Myers Squibb in August 2012, Mark was the senior vice president of corporate development where he served as a member of the executive committee with responsibility for strategy, business development and alliance management. Previously, he also held leadership positions with CardioNet (now Biotelemetry), Advance Tissue Sciences, and Medtronic. Mr. Gergen holds a J.D. from the University of Minnesota Law School and a B.A. in Business Administration from Minot State University.\nAbout Poseida Therapeutics Inc.\nPoseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com .\nCorporate Communications Contact:\nJason Spark\nCanale Communications\n619-849-6005\nJason@canalecomm.com\nSource:Poseida Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=0SeUypENMgsMLf60Cu1Gjgt5YY8Ix7VRXi2Y-_r3mUK9EU4ZlxgZdzAmLuOJRzEWyDcpZX4ok3AV7_WSCzJwuSBy3dkCegraCFSPUTRz5TA=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/cce14b2e-e020-4ad0-b653-e0e601e215fd", "https://www.globenewswire.com/Tracker?data=B1TQYEZJ3fysONduhlnYgULQdkLJrs2FK6io0sBjTLu0u3EG6TGbYT8-Pyp-X2K6D3XAUXugKEMVEYOJgC0KQg=="], "published": "2018-02-28T16:00:00.000+02:00", "crawled": "2018-02-28T17:50:52.033+02:00", "highlightTitle": ""}